This multicenter, open-label, single-arm extension study will evaluate the long-term safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Patients who have completed the MA21488 core study and the ML21530 study and who could benefit from the study drug, according to the opinion of the investigator, will receive 8 mg/kg of intravenous RoActemra/Actemra every four weeks. The anticipated time on study treatment is 104 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01715831?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
